請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37169
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張上淳(Shan-Chwen Chang) | |
dc.contributor.author | Ching-Shiang Yang | en |
dc.contributor.author | 楊晴翔 | zh_TW |
dc.date.accessioned | 2021-06-13T15:20:31Z | - |
dc.date.available | 2013-08-08 | |
dc.date.copyright | 2008-08-08 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-23 | |
dc.identifier.citation | 1. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007;55(3):254-9.
2. Kang CI, Cheong HS, Chung DR, et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2008;27(1):85-8. 3. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11(6):315-7. 4. Jacoby GA. Beta-lactamase nomenclature. Antimicrob Agents Chemother 2006;50(4):1123-9. 5. Yu W-L, Chuang Y-C, Walther-Rasmussen J. Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect 2006;39(4):264-77. 6. Kang C-I, Kim S-H, Park WB, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004;48(12):4574-81. 7. Martinez JA, Aguilar J, Almela M, et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother 2006;58(5):1082-5. 8. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18(4):657-86. 9. Liao CH, Sheng WH, Wang JT, et al. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan. J Microbiol Immunol Infect 2006;39(1):59-66. 10. Wanke CA. Enteropathogenic and enteroaggregative strains of Escherichia coli: clinical features of infection, epidemiology, and pathogenesis. Curr Clin Top Infect Dis 1995;15:230-52. 11. Orskov F, Orskov I. Escherichia coli serotyping and disease in man and animals. Can J Microbiol 1992;38(7):699-704. 12. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998;11(1):142-201. 13. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 1996;24(5):380-8. 14. Hsueh PR, Chen ML, Sun CC, et al. Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. Emerg Infect Dis 2002;8(1):63-8. 15. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Infect Control 2006;34(5 Suppl 1):S3-10; discussion S64-73. 16. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14(4):933-51, table of contents. 17. Harder KJ, Nikaido H, Matsuhashi M. Mutants of Escherichia coli that are resistant to certain beta-lactam compounds lack the ompF porin. Antimicrob Agents Chemother 1981;20(4):549-52. 18. Oliver A, Weigel LM, Rasheed JK, McGowan Jr JE, Jr., Raney P, Tenover FC. Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob Agents Chemother 2002;46(12):3829-36. 19. Coudron PE, Moland ES, Thomson KS. Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol 2000;38(5):1791-6. 20. Willmott CJ, Maxwell A. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob Agents Chemother 1993;37(1):126-7. 21. Cohen SP, Hooper DC, Wolfson JS, Souza KS, McMurry LM, Levy SB. Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother 1988;32(8):1187-91. 22. Perlin MH, Lerner SA. High-level amikacin resistance in Escherichia coli due to phosphorylation and impaired aminoglycoside uptake. Antimicrob Agents Chemother 1986;29(2):216-24. 23. Pfaller MA, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. Clin Infect Dis 2006;42 (Suppl 4):S153-63. 24. Livermore DM. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8(4):557-84. 25. Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. Curr Opin Pharmacol 2007;7(5):459-69. 26. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005;352(4):380-91. 27. Sougakoff W, Goussard S, Gerbaud G, Courvalin P. Plasmid-mediated resistance to third-generation cephalosporins caused by point mutations in TEM-type penicillinase genes. Rev Infect Dis 1988;10(4):879-84. 28. Jacoby GA. Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams. Infect Dis Clin North Am 1997;11(4):875-87. 29. Bin C, Hui W, Renyuan Z, et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 2006;56(4):351-7. 30. Tzouvelekis LS, Tzelepi E, Tassios PT, Legakis NJ. CTX-M-type beta-lactamases: an emerging group of extended-spectrum enzymes. Int J Antimicrob Agents 2000;14(2):137-42. 31. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother 1993;37(4):851-8. 32. Yan JJ, Ko WC, Tsai SH, Wu HM, Jin YT, Wu JJ. Dissemination of CTX-M-3 and CMY-2 beta-lactamases among clinical isolates of Escherichia coli in southern Taiwan. J Clin Microbiol 2000;38(12):4320-5. 33. Poirel L, Girlich D, Naas T, Nordmann P. OXA-28, an extended-spectrum variant of OXA-10 beta-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob Agents Chemother 2001;45(2):447-53. 34. National Committee for Clinical Laboratory Standards, Wayne P. Performance standards for antimicrobial susceptibility testing. Ninth information supplement,. National Committee for Clinical Laboratory Standards 1999:M100–S9. 35. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007;60(5):913-20. 36. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006;50(4):1257-62. 37. Rodriguez-Bano J, Navarro MD, Romero L, et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006;42(1):37-45. 38. Bellissimo-Rodrigues F, Gomes AC, Passos AD, Achcar JA, Perdona Gda S, Martinez R. Clinical outcome and risk factors related to extended-spectrum beta-lactamase-producing Klebsiella spp. infection among hospitalized patients. Mem Inst Oswaldo Cruz 2006;101(4):415-21. 39. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281(6):517-23. 40. Calbo E, Romani V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006;57(4):780-3. 41. Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8(3):159-66. 42. Gales AC, Sader HS, Jones RN. Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis 2002;44(3):289-99. 43. Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis 2002;42(3):193-8. 44. Bell JM, Chitsaz M, Turnidge JD, Barton M, Walters LJ, Jones RN. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program. J Clin Microbiol 2007;45(5):1478-82. 45. Hirakata Y, Matsuda J, Miyazaki Y, et al. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis 2005;52(4):323-9. 46. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001;32 Suppl 2:S94-103. 47. European Antimicrobial Resistance Surveillance System. EARSS annual report 2006. (Accessed at http://www.rivm.nl/earss/Images/EARSS%202006%20Def_tcm61-44176.pdf.) 48. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55(6):965-73. 49. Wu TL, Chia JH, Su LH, Chu C, Kuo AJ, Chiu CH. Dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae in intensive care units of a medical center in Taiwan. Microb Drug Resist 2006;12(3):203-9. 50. Behar PR, Teixeira PJ, Fachel JM, Kalil AC. The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study. J Hosp Infect 2008;68(2):123-9. 51. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004;140(1):26-32. 52. Skippen I, Shemko M, Turton J, Kaufmann ME, Palmer C, Shetty N. Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London. J Hosp Infect 2006;64(2):115-23. 53. Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control 2005;33(6):326-32. 54. Du B, Long Y, Liu H, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002;28(12):1718-23. 55. Sturenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003;47(4):273-95. 56. Rodriguez-Bano J, Navarro MD, Romero L, et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect 2008;14(2):180-3. 57. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am J Infect Control 2007;35(9):606-12. 58. Pena C, Gudiol C, Tubau F, et al. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect 2006;12(3):279-84. 59. Yan JJ, Ko WC, Wu JJ, Tsai SH, Chuang CL. Epidemiological investigation of bloodstream infections by extended spectrum cephalosporin-resistant Escherichia coli in a Taiwanese teaching hospital. J Clin Microbiol 2004;42(7):3329-32. 60. Rodriguez-Bano J, Navarro MD, Romero L, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42(3):1089-94. 61. Ho P-L, Chan W-M, Tsang KWT, Wong SSY, Young K. Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 2002;34(8):567-73. 62. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Predictors of mortality among patients with community-onset infection due to extended-spectrum beta-lactamase-producing Escherichia coli in Thailand. Infect Control Hosp Epidemiol 2008;29(1):80-2. 63. Hsueh PR, Snyder TA, Dinubile MJ, Satischandran V, McCarroll K, Chow JW. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2006;28(3):238-43. 64. Sorlozano A, Gutierrez J, Romero JM, de Dios Luna J, Damas M, Piedrola G. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli. J Basic Microbiol 2007;47(5):413-6. 65. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008;9(1):23-37. 66. Bhavnani SM, Ambrose PG, Craig WA, Dudley MN, Jones RN. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006;54(3):231-6. 67. Yamaguchi K, Ishii Y, Iwata M, et al. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006. Jpn J Antibiot 2007;60(6):344-77. 68. Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis 2008;61(2):203-13. 69. Berg ML, Crank CW, Philbrick AH, Hayden MK. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report. Ann Pharmacother 2008;42(2):207-12. 70. Mody RM, Erwin DP, Summers AM, et al. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms. Ann Clin Microbiol Antimicrob 2007;6:6. 71. Teng CP, Chen HH, Chan J, Lye DC. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections. Int J Antimicrob Agents 2007;30(4):356-9. 72. Betriu C, Salso S, Sanchez A, et al. Comparative in vitro activity and the inoculum effect of ertapenem against Enterobacteriaceae resistant to extended-spectrum cephalosporins. Int J Antimicrob Agents 2006;28(1):1-5. 73. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67(7):1027-52. 74. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45(12):3548-54. 75. Labombardi VJ, Rojtman A, Tran K. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagn Microbiol Infect Dis 2006;56(3):313-5. 76. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003;47(11):3442-7. 77. Miller LA, Ratnam K, Payne DJ. Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr Opin Pharmacol 2001;1(5):451-8. 78. Netzel TC, Jindani I, Hanson N, Turner BM, Smith L, Rand KH. The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum beta-lactamases in Escherichia coli. Diagn Microbiol Infect Dis 2007;58(3):345-8. 79. Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005;41(7):923-9. 80. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2005;49(5):2137-9. 81. Goyanes MJ, Cercenado E, Insa R, Morente A, Alcala L, Bouza E. High rates of antimicrobial co-resistance among Enterobacteriaceae: comparative analysis between clinical isolates resistant and susceptible to third-generation cephalosporins. Rev Esp Quimioter 2007;20(2):216-21. 82. Dawis MA, Isenberg HD, France KA, Jenkins SG. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. J Antimicrob Chemother 2003;51(5):1203-11. 83. Drago L, De Vecchi E, Nicola L, Legnani D, Lombardi A, Gismondo MR. In vitro synergy and selection of resistance by fluoroquinolones plus amikacin or beta-lactams against extended-spectrum beta-lactamase-producing Escherichia coli. J Chemother 2005;17(1):46-53. 84. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4(8):519-27. 85. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008;52(2):570-3. 86. Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008;14 (Suppl 1):198-202. 87. Ko KS, Suh JY, Peck KR, et al. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis 2007;58(1):111-5. 88. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007;29(1):62-5. 89. Pena C, Gudiol C, Calatayud L, et al. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality. J Hosp Infect 2008;68(2):116-22. 90. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.[erratum appears in Antimicrob Agents Chemother. 2007 Sep;51(9):3469]. Antimicrob Agents Chemother 2007;51(6):1987-94. 91. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373-83. 92. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31(4):1250-6. 93. Cheong HS, Kang CI, Kwon KT, et al. Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteraemia. J Antimicrob Chemother 2007;60(6):1355-60. 94. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. [CDC definitions for nosocomial infections 1988]. Z Arztl Fortbild (Jena) 1991;85(17):818-27. 95. Valles J, Calbo E, Anoro E, et al. Bloodstream infections in adults: importance of healthcare-associated infections. J Infect 2008;56(1):27-34. 96. Rodriguez-Bano J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006;43(11):1407-14. 97. Kim YK, Pai H, Lee HJ, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002;46(5):1481-91. 98. Metan G, Zarakolu P, Cakir B, Hascelik G, Uzun O. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents 2005;26(3):254-7. 99. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Clin Infect Dis 2004;39(6):812-8. 100. Wisplinghoff H, Cornely OA, Moser S, et al. Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. Infect Control Hosp Epidemiol 2003;24(12):905-11. 101. Suljagic V, Cobeljic M, Jankovic S, et al. Nosocomial bloodstream infections in ICU and non-ICU patients. Am J Infect Control 2005;33(6):333-40. 102. Pittet D, Li N, Wenzel RP. Association of secondary and polymicrobial nosocomial bloodstream infections with higher mortality. Eur J Clin Microbiol Infect Dis 1993;12(11):813-9. 103. Marra AR, Bearman GM, Wenzel RP, Edmond MB. Comparison of the systemic inflammatory response syndrome between monomicrobial and polymicrobial Pseudomonas aeruginosa nosocomial bloodstream infections. BMC Infect Dis 2005;5:94. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37169 | - |
dc.description.abstract | 目的:
此病例對照分析研究主要是為了了解感染廣效乙內醯胺酶(extended-spectrum β-lactamase;ESBL)大腸桿菌(Escherichia coli;E. coli)菌血症的危險因子,另外針對經驗性抗生素恰當與否及不同抗生素治療對於臨床治療效果作進一步的評估,最後找出影響病人死亡的危險因子以提供醫療人員在臨床上選擇抗生素的參考。 設計: 自2005年1月1日至2007年6月30日為期30個月的單醫學中心回溯性病例對照分析研究,以病歷回顧方式進行。 地點: 國立台灣大學醫學院附設醫院—位於台灣北部的一間擁有2200張病床的教學醫院。 對象: 病例組及對照組的病人都是經由台大醫院細菌室報告至少有一套血液培養長出大腸桿菌且伴隨有發燒及/或其它感染徵兆之16歲以上患者。將感染ESBL E. coli菌血症的病人定為病例組,根據檢體採檢日期最接近的日期以1:1比例配對選取出感染non-ESBL E. coli菌血症的病人定為對照組。每一位病人只納入其第一次的感染。 方法: 利用查閱病人紙本病歷及電子病歷的方法記錄病人的基本資料、合併症、和這次住院相關的資訊、過去住院或感染大腸桿菌的病史、在菌血症發作前抗生素的使用情況、感染菌血症時的臨床表徵、感染時所使用的的抗生素治療、病人的預後等等。本研究的觀察終點為菌血症發作第30天的死亡率。 在危險因子和預後的分析主要利用單變項分析及多變項羅吉斯迴歸分析。在存活方面利用Kaplan-Meier法作存活分析圖及Log-rank法去比較。 結果: 研究期間共有97位感染ESBL E. coli菌血症的病人,有五位病人因為追蹤不完全,另外一位病人因為無法借閱病歷而被排除。同時配對91位感染non-ESBL E. coli菌血症病人。在病例組的91位病人中有71位病人屬於單一菌種感染(78%),20位病人是多重菌種感染(22%)。兩組的第30天死亡率分別為病例組28.6%、對照組9.9% (p = 0.001)。在多變項分析中發現感染當時有留置尿管的病人(勝算比為6.21,p = 0.003)、發生菌血症前30天內曾使用過第三代或第四代cephalosporins(勝算比為5.16,p = 0.046)、以及發生菌血症前30天內使用過抗生素(勝算比為2.93,p = 0.021)為感染ESBL E. coli菌血症的獨立危險因子;反之,社區型感染(勝算比為0.22,p = 0.002)為感染ESBL E. coli菌血症的保護因子。在治療方面,病例組病人中給予經驗性抗生素治療恰當與否對第30天的死亡率並沒有顯著差異(p = 0.382),即使是分析單一菌種感染的病人也得到相同的結果(p = 0.233)。若分析確切治療中carbapenem組及non-carbapenem組兩組的第30天死亡率也沒有顯著的差異(p = 0.703)。最後,對於死亡危險因子的分析可發現在全體病例病人中,若病人是在加護病房得到感染(勝算比為7.47,p = 0.006)、本身是免疫抑制的病人(勝算比為3.82,p = 0.018)、原發性菌血症感染的病人(勝算比為3.15,p = 0.045)都是影響死亡的危險因子。分析單一菌種感染的病人發現病人若感染時出現敗血性休克的情況(勝算比為7.01,p = 0.003)是一危險因子,而在加護病房得到感染(勝算比為6.92,p = 0.017)依然是一獨立危險因子。 結論: 當病人過去使用過抗生素,尤其是廣效的cephalosporin(第三代及第四代)及感染當時有留置尿管的病人,都要小心ESBL E. coli菌血症發生的可能性;反之,如果是社區型的感染則發生ESBL E. coli菌血症的機會會比較低。在本研究中對於感染ESBL E. coli菌血症的病人,一開始給予恰不恰當的經驗性抗生素並不會明顯影響預後,在嚴重的病人中還是以carbapenem為首選藥物。如果病人本身免疫功能不全、原發性菌血症感染的病人、感染當時病人有出現敗血性休克的情況及在加護病房感染的病人往往都會是死亡率較高的危險族群。 關鍵詞: 廣效性乙內醯胺酶、大腸桿菌、菌血症、危險因子、抗藥性、病例對照研究、治療效果、死亡率 | zh_TW |
dc.description.abstract | Objective:
A case-control study was conducted in order to identify the risk factors associated with bloodstream infection caused by extended-spectrum-β- lactamase (ESBL) producing Escherichia coli (E. coli). Secondly, to evaluate the impact of different antibiotics and adequate empirical treatment on clinical outcomes. And also to find out the risk factors for mortality of ESBL-producing E. coli bacteremia in order to provide a concept for clinicians to choose appropriate antibiotic therapy. Design: A retrospective case-control chart-review study was conducted during a 30-month period between Jaunary 2005 and June 2007. Setting: National Taiwan University Hospital---a 2200-bed teaching hospital in northern Taiwan Patients: Both case and control patients were identified by systemically reviewing the results from the microbiology laboratory. “Case patients” were those who had ESBL-positive E. coli bactermia. One case patient was matched with one control patient according to the closest date to isolation of ESBL-positive E. coli. “Control patients” were those who had ESBL-negitive E. coli bacteremia. We only included the first episode of each patient. Methods: Data were collected from medical records and hospital computerized databases. The records for each patient including patients’ profiles, underlying diseases and comorbidities, the informations about this admission, previous hospitalization histories, previous E. coli infection or colonization histories, antibiotics exposure before bacteremia onset, clinical presentations when bacteremia onset, antibiotic regimens during treatment period, clinical outcomes after bacteremia onset. The primary endpoint was 30-day mortality. Risk factors and clinical outcomes were examed using univariate analysis and muitiple logistic regression analysis. Survival curves shown by Kaplan-Meier method were compared with Log-rank test. Results: During the study period, there were 97 patients of ESBL E. coli bacteremia, 5 patients were excluded because of incomplete follow up and 1 patient with missing chart. Then 91 control patients were matched. In case group, there were 71 (78.0%) monomicrobial infections and 20 polymicrobial infections. The 30 day mortality was 28.6% (26/91) in the case group, compared to 9.9% (9/91) in the control group (p = 0.001).By multivariate analysis, urinary catheterization [odds ratio(OR)6.21, p = 0.003], previous treatment with 3rd、4th-cephalosporins [odds ratio(OR)5.16, p = 0.046], prior exposure to antibiotics [odds ratio(OR)2.93, p = 0.021] were independent predictors for ESBL production. On the contrary, community-acquired infection [odds ratio(OR)0.22, p = 0.002] was a protective factor for ESBL production. Analyses of treatment outcomes showed that there was no significant difference between patients received adequate or inadequate empirical therapy for case patients (p = 0.382) and monomicrobial infection patients (p = 0.233). Comparison between carbapenem and non-carbapenem treatment groups also showed no significant influence on the 30-day mortality (p = 0.703). Multivariate logistic regression analysis for all case patients showed that ICU-acquired [odds ratio(OR)7.47, p = 0.006], immunocompromised patients [odds ratio(OR)3.82, p = 0.018], primary bacteremia [odds ratio(OR)3.15, p = 0.045] were independent risk factors for 30-day mortality. The results from monomicrobial infection patients showed that septic shock [odds ratio(OR)7.01, p = 0.003], ICU-acquired [odds ratio(OR)6.92, p = 0.017] were risk factor for 30-day mortality. Conclusions: Our results showed that prior exposure antibiotics, especially 3rd or 4th- cephalosporins, and urinary catheterization were independent predictors for ESBL production. On the contrary, community-acquired infection was a predictor for non-ESBL E. coli bacteremia. Appropriateness of empirical therapy and regimens of definitive therapy did not significantly influence mortality on day 30 in our study. Carbapenem is still the drug of choice for severe patients. Immunocompromised patients, primary bacteremia, septic shock and ICU-acquired infection had a significant impact on day 30 mortality. Keywords: extended-spectrum-β- lactamase(ESBL), Escherichia coli(E. coli), bacteremia, risk factor, resistant, case-control study, treatment outcome, mortality | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T15:20:31Z (GMT). No. of bitstreams: 1 ntu-97-R95451007-1.pdf: 9012113 bytes, checksum: 89636eebc398abb31ec7848a18bc6317 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 誌謝 ii
中文摘要 iii Abstract vi 目錄 ix 圖目錄 xii 表目錄 xiii 第1章 緒論 1 第1節 研究背景 1 第2節 研究目的 3 第2章 文獻回顧 4 第1節 細菌學 4 第2節 流行病學相關研究 10 第3節 帶有廣效乙內醯胺酶大腸桿菌的危險因子 12 第4節 對於帶有廣效乙內醯胺酶大腸桿菌的治療方式 15 第5節 對於帶有廣效乙內醯胺酶大腸桿菌的預後因子 19 第3章 研究方法 23 第1節 研究架構 23 第2節 研究地點及研究對象 24 第3節 資料收集:變項及定義 25 第4節 統計分析方法 30 第4章 研究結果 32 第1節 收案病人數 32 第2節 基本資料 33 第3節 病人過去病史及相關合併症 35 第4節 容易得到ESBL E. coli的危險因子分析 36 第5節 過去所使用的抗生素分類情形 37 第6節 菌血症發作當時的疾病嚴重程度及感染來源 39 第7節 治療ESBL E. coli菌血症所使用抗生素情形 40 第8節 死亡率 43 第9節 Carbapenem對於單一感染ESBL E. coli菌血症的治療效果 48 第10節 抗藥性分析 51 第11節 存活分析 52 第12節 危險因子分析 57 第5章 討論 71 第1節 感染ESBL E. coli菌血症之危險因子 71 第2節 不同抗生素治療結果比較 73 第3節 死亡率 77 第4節 影響感染ESBL E. coli菌血症死亡之危險因子 78 第5節 研究限制 86 第6章 結論 89 第7章 參考文獻 91 | |
dc.language.iso | zh-TW | |
dc.title | 帶有廣效乙內醯胺酶大腸桿菌菌血症之
感染危險因子及死亡危險因子分析:著重於藥物治療 | zh_TW |
dc.title | Analysis of risk factors and prognosis factors for Extended-Spectrum-β-lactamase-Producing E. coli Bacteremia with emphasis on treatment regimen | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林慧玲(Fei-Lin Lin),陳宜君(Yee-Chun Chen),林淑文(Shu-Wen Lin) | |
dc.subject.keyword | 廣效性乙內醯胺酶,大腸桿菌,菌血症,危險因子,抗藥性,病例對照研究,治療效果,死亡率, | zh_TW |
dc.subject.keyword | extended-spectrum-β- lactamase(ESBL),Escherichia coli(E. coli),bacteremia,risk factor,resistant,case-control study,treatment outcome,mortality, | en |
dc.relation.page | 117 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-07-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 8.8 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。